Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-MG
NCT03863080Phase 2Completed
- Sponsor
- Immunovant, Inc.
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of batoclimab in myasthenia gravis (MG) (3 arms), sponsored by Immunovant, Inc. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events at 18 weeks, Number of Participants With Clinically Significant Changes in Vital Signs at 18 weeks and 5 more. Started May 2019; status: completed.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT03863080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863080.